Independent. Not owned by or funded by any pharmaceutical manufacturer.
Evidence-sourced · medically-reviewed where indicated
GLP-1 HealthcareThe independent GLP-1 resource
Accountability

What we cover, and what we don’t

Most health sites imply they cover their subject completely. We keep a map of GLP-1 receptor agonists broken into 82 subjects and report against it here — 79 written, 3 not. Every gap has a stated reason, and 2 of them are subjects we have decided not to write at all.

Subjects mapped
82
Written
79
Still open
3
Coverage
96%

That percentage counts subjects, not traffic. Weighting it by how many people search for each one would let a single popular page paper over a dozen missing ones.

What the map itself is missing

A coverage figure is only as honest as the map it counts against, so here is what ours does not yet contain. The subject list was built from two keyword studies — one of terms containing “GLP-1”, one of terms containing “semaglutide”. The second was added after the first turned out to be missing most of how people actually talk about these medicines, and it roughly doubled what we knew we were missing.

Two studies are still not done: the brand names on their own — Ozempic, Wegovy, Mounjaro, Zepbound — and a systematic comparison against what other sites in this category cover. Two competitor pages have now been read closely, keyword by keyword, which is what added the four cost and access subjects below and dropped our coverage figure when it did; two pages are not a survey. Until those studies exist, treat the percentage above as coverage of what we have thought to look for, which is not the same thing as coverage of the subject.

Where two of our own pages could have overlapped

Adding a subject is the easy half. The harder half is making sure a new page answers a question no existing page was already answering — otherwise two of our pages compete to answer one question and both do it worse. For the places where that risk is real, we write down which page owns which question, and the build refuses to ship if two of them claim the same one.

Cost & coverage
Whether your insurance will cover a GLP-1, which savings programmes you are eligible for, and what to do when a claim is denied.
The cheapest routes, priced
Which way of paying for a GLP-1 costs least for someone in your situation — insurance, Medicare, buying direct, or a telehealth membership.
Price tracker
How published GLP-1 prices have changed over time, and which announced changes have not taken effect yet.
What semaglutide costs
What semaglutide costs by the form you take it in — injection, tablet, or compounded — and which providers supply each.
What tirzepatide costs
What tirzepatide costs, why there is no tablet to fall back on, and which providers supply the brand and compounded routes.
GLP-1s and immunosuppression
Whether a GLP-1 is safe to take alongside immunosuppressant medication, and what it does to tacrolimus levels.
GLP-1s and autoimmune disease
Whether GLP-1 medications suppress immunity, reduce inflammation, or do anything to an autoimmune disease — and what has actually been studied in each condition.
Microdosing
What microdosing a GLP-1 means, what is claimed for it, and what the labels and evidence support at sub-therapeutic doses.
GLP-1 patch
Whether a GLP-1 patch can deliver the medication, what the products sold under that name contain, and why the reviews describe weight loss anyway.
GLP-1 gummies
Whether GLP-1 gummies contain a GLP-1 medication, and what is actually in them.
Where to buy
The imperative question — I have decided, where do I actually go — answered as a sequence of four decisions rather than a provider comparison.
Walgreens & CVS
What Walgreens and CVS charge to prescribe a GLP-1, and how a per-visit fee compares with a telehealth membership.
Overseas pharmacies
Whether buying a GLP-1 from a Canadian or overseas pharmacy is lawful, and what the FDA's published importation conditions actually say.
Finding care
Who the telehealth GLP-1 providers are and what each publishes about its own terms, unranked.
WeightWatchers Clinic
What WeightWatchers Clinic publishes about its own terms — access model, prescriber type, medications, pricing and compounding disclosures — as verified on a dated sweep.
Mochi Health
What Mochi Health publishes about its own terms — access model, prescriber type, medications, pricing and compounding disclosures — as verified on a dated sweep.
Willow Health
What Willow publishes about its own terms — access model, prescriber type, medications, pricing and compounding disclosures — as verified on a dated sweep.
Hims & Hers
What Hims & Hers publishes about its own terms — access model, prescriber type, medications, pricing and compounding disclosures — as verified on a dated sweep.
Ro (Body)
What Ro publishes about its own terms — access model, prescriber type, medications, pricing and compounding disclosures — as verified on a dated sweep.
Amazon One Medical
What Amazon One Medical publishes about its own terms — access model, prescriber type, medications, pricing and compounding disclosures — as verified on a dated sweep.
Noom Med
What Noom Med publishes about its own terms — access model, prescriber type, medications, pricing and compounding disclosures — as verified on a dated sweep.
Liraglutide vs semaglutide
How liraglutide and semaglutide compare when they have been randomised against each other, rather than inferred across separate trials.
Lawsuits
What the FDA labels of the litigated GLP-1 products say about the injuries being alleged, for someone who wants the facts rather than a lawyer.

Why we publish this

A site that never says what it is missing is asking you to assume it is missing nothing. We would rather you could see the edges. It also keeps us honest internally: a subject with a reason attached is one someone decided about, and a subject without one is how a topic quietly stops being tracked.

The list below is the whole map. Where a subject is covered by a page with a different name than you might expect, the reason is given — usually because two planned pages turned out to be one real question, and splitting them would have produced two thin pages instead of one useful one.

Questions we can see being asked, and have not answered

The list above is organised by subject. This one is organised by what people actually type, taken from a study of the pages that currently outrank us, and it is the more uncomfortable of the two — these are not subjects we have not thought of, they are questions we can watch being asked and have not yet earned the right to answer.

“glp1 forum”
Difficulty 2 and deliberately unclaimed. The intent is to reach other patients, not to read a publisher, and building something that ranks for it without being a community would be answering a question we cannot answer.
“tirzepatide cost goodrx”
Discount cards are a payment route our cost model does not contain. Adding one means reading what the card publishes for these drugs and dating it.

The pattern in them is one thing: almost all are phrased as where do I buy this rather than what does this cost. We have built the second and not the first, and a page that answers it well is a different shape from anything currently on this site — a sequence rather than a comparison. Publishing that here is partly so we cannot quietly decide it was never a gap.

Fundamentals

Drug reference

  • Ozempic
  • Wegovy
  • Mounjaro
  • Zepbound
  • Semaglutide — Planned as a molecule page. Molecule-level questions are answered on the comparisons page; the products carrying the molecule each have their own record.
  • Tirzepatide — Same as semaglutide: the molecule is covered through its products and the class comparison rather than a page of its own.

Comparisons

Delivery formats

Dosing

  • Dosing and titration
  • Injection sites and rotation
  • Titration schedules by product — This was a deliberate gap until 12 August 2026, on the grounds that a dose-by-dose schedule is prescribing information and reproducing one second-hand is what the drug pages exist to refuse. That reasoning was about second-hand charts, and it still stands against them. The tracker is a different artefact: every ladder is read from the product's own FDA label, and the tool is built around the sentence those charts leave out — that the early doses are initiation and escalation dosages, not approved maintenance dosages. The decision changed when we found a way to publish the numbers and that sentence together.
  • Titration and dose escalation — The dosing hub explains what titration is for; the tracker answers where you are in it and what the label permits. Volume is a manual estimate across the schedule and missed-dose variants, not an Ahrefs cell.
  • Storing a GLP-1, and travelling with one — Written as a safety question rather than a convenience one, and it produced the page's strongest finding: the labels give five different out-of-fridge allowances, 14 to 56 days, several conditional on whether the pen has been used. Two products from one manufacturer containing one molecule carry different numbers.

Safety

  • Side effects: common and serious
  • Is GLP-1 safe?
  • Taking a GLP-1 alongside immunosuppressants — Written before this map tracked it. Recorded now because its sibling page made the pair visible, and an untracked page is one that can be quietly dropped.
  • GLP-1s, immunity and autoimmune disease
  • Hair loss
  • Constipation
  • “Ozempic face”
  • Alcohol
  • Sleep apnoea
  • Long-term side effects — Absorbed rather than written. The honest version of this subject is that the evidence horizon is short, and that argument — with the follow-up durations drawn against how long people actually take these — is the centrepiece of the safety page. A separate page would have competed with it while saying less.
  • Interactions with other medications and everyday substances — The whole 'can I take X with a GLP-1' query template is served by one page with a lookup rather than one page per substance. The labels share a single mechanism and a handful of specifics, so per-substance pages would repeat one answer behind many titles — which is the pattern this site exists not to be. Volume is a manual estimate across the template, not an Ahrefs cell.
  • How long a GLP-1 takes to work — Answered by refusing the premise, which is what the labels support: none of them states a time until the drug starts working, and only three of nine state even when blood levels plateau. The page says so and then gives the better explanation — that the early doses are not treatment doses — with the titration tracker beside it.
  • How long a GLP-1 stays in your system — Filed with the onset question rather than alone, because both are answered by the same pharmacokinetics section of the same labels. The half-life range across the class turned out to be more than a hundredfold, from 2.4 hours to a week.
  • Which GLP-1 has the fewest side effects — The data was already on the site and the question was not. Answered now under its own heading on the side-effects hub, and answered honestly: the per-drug columns come from separate trials and cannot be ranked against each other, the one head-to-head found a similarity rather than a winner, and the useful question is which effects you would find hardest to live with.
  • What happens when you stop taking one — Covered thinly and in the wrong place: the calculator explains that the appetite effect depends on the drug being present, and the cost hub repeats it. Neither is where someone typing this question would land. Recorded as covered because the answer exists and is correct, not because the coverage is good.

Cost

  • Cost and insurance coverage
  • The cheapest way to get a GLP-1 — Planned at /glp-1/cost/cheapest-glp-1.
  • Getting a GLP-1 without insurance — Not written as a separate page, deliberately. The cheapest-routes comparison already carries a section under this exact heading and prices every cash-pay route on the page. A second page targeting the same question would have competed with the strongest commercial page on the site.
  • What insurance actually covers — The cost hub is the page for this: its pathway tool branches on insurance status, and it covers denials, appeal deadlines, and formulary and step-therapy exceptions. A third page competing on the word insurance would have split the cluster rather than added to it.
  • What semaglutide costs, by form — No volume recorded: the competitor export we added this topic from covers their tirzepatide page and their molecule-agnostic page, not their semaglutide one, so we have that page's ranking history but not its keywords. Borrowing the tirzepatide figure would be inventing one. The page owns its queries in lib/page-scope.ts.
  • What tirzepatide costs — Volume is the four cost-phrased tirzepatide terms in the 21 August competitor export added together — 'tirzepatide generic price' 4,100, 'how much is tirzepatide' 3,900, 'cheapest tirzepatide' 1,700 and 'tirzepatide cost per month' 1,200 — not the whole 110,720 the page ranks for, most of which is the buying axis recorded separately below. Kept as a separate topic from semaglutide because the answer differs on the facts, not only on the noun.
  • Whether a generic GLP-1 exists — Answered on both molecule cost pages from FDA application data rather than asserted: no ANDA exists for semaglutide or tirzepatide, and eight exist for liraglutide. Volume is the tirzepatide terms only, since the competitor export we have covers that page; the semaglutide equivalents are certainly asked too and are not counted here.
  • Buying from a Canadian or international pharmacy
  • Whether GoodRx and discount cards work on a GLP-1 NOT WRITTEN — Not written, and on current evidence not writable to this site's standard. The rule here is that a price is read from the seller's own page on a stated date. Both major discount-card sites are behind commercial bot protection — GoodRx returns a PerimeterX challenge, SingleCare a DataDome one — and we will not defeat a CAPTCHA to take data a site has said it does not want taken. That is a decision rather than a delay: the remaining routes are a human reading the sites by hand and recording what they saw, or citing a third party who did. Until one of those happens this stays a gap, because the alternative is a page of plausible-sounding generalities about prices nobody here has seen.
  • The Medicare bridge programme

Access

Diet

Microdosing

Natural alternatives

Molecule

  • Semaglutide, the molecule — The largest single term in either export, and the hardest. Answered today by the class/molecule/brand page and the drug reference between them. Whether it deserves a dedicated molecule page is the biggest open question on this map — at KD 84 it is not a quick win, and a thin page would be worse than the current arrangement.
  • Semaglutide vs tirzepatide
  • Liraglutide vs semaglutide — Given its own page on 2026-09-07, correcting a decision made on a false premise. The previous note here said these two molecules had 'no head-to-head weight trial behind them' and folded the topic into the tirzepatide comparison on that basis. They have one: STEP 8 (JAMA 2022) randomised 338 adults to semaglutide 2.4mg or liraglutide 3.0mg for 68 weeks. The fold was not a judgement that turned out badly, it was a factual error about what evidence exists — and it hid the topic behind a page that never mentions liraglutide at all.
  • Compounded semaglutide
  • Fatigue and tiredness
  • Which drugs are GLP-1s, and which are mistaken for them — Added from search data rather than from the keyword studies this map was built on, which is the point. Neither study sampled brand names, so a whole classification intent — people asking whether their own drug is one of these — was invisible to the plan until Search Console showed it.
  • The older GLP-1 agonists: Trulicity, Victoza, Byetta — Covered by four product pages — Trulicity, Victoza, Saxenda and Byetta — added 2026-08-17, a day after this topic was first recorded as a gap. Bydureon is deliberately not among them: no current US prescribing information for it could be found on DailyMed, and we will not describe a product as available on that basis.
  • Dosage charts and unit conversion NOT WRITTEN — Roughly 130,400 a month across 224 dosing, unit and conversion terms, and we serve half of it. The schedule half is now covered: the titration tracker publishes each product's ladder, read from its own FDA label. What stays refused is the unit-conversion half — turning syringe units into milligrams — because that is a measurement-safety question rather than a reference one, and the arithmetic depends on a concentration the reader has to get right first. It is answered on the reconstitution guide, which explains why converting units to milligrams from a web page is how people overdose.
  • Where to inject semaglutide — Answered in full, including the rotation pattern, under the class-level name.
  • Buying semaglutide online — The process page answers what happens; the directory answers who. Between them this is served without a third page competing on the word online.
  • Results and before-and-after — Moved off /glp-1/statistics on 2026-08-11. The statistics page holds the trial-efficacy figures as a population reference; the calculator answers the same demand as a personal question, which is what this query actually is. We still do not publish before-and-after photography or user reviews, which is what much of this demand is looking for, and we are not going to.
  • Weight-loss calculator — The volume figure is a manual estimate across the calculator variants, not an Ahrefs cell — neither keyword pull was seeded on 'calculator'. Flagged so it is not mistaken for sourced data when the next study lands.

Trust

  • About the publisher
  • Editorial policy — Planned at /about/editorial-policy.
  • Medical review board NOT WRITTEN — Cannot be written. A review board page needs real clinicians who have agreed to review under their own names and credentials. Publishing one without them would be the single most damaging thing this site could do.

What is deliberately absent, and stays absent

2 subjects on that list are not waiting to be written. They are decisions, and they are the most useful things on this page.

Think something is missing?

The map is ours, and it is not the last word on what people actually need. If there is a question about GLP-1 receptor agonists you came here with and could not find an answer to, tell us at hello@glp1.healthcare. Gaps someone has actually hit are worth more than gaps we predicted.